Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcturus Therapeutics Holdings (ARCT) EBIT Margin (2018 - 2025)

Arcturus Therapeutics Holdings' EBIT Margin history spans 8 years, with the latest figure at 435.06% for Q4 2025.

  • For Q4 2025, EBIT Margin fell 28838.0% year-over-year to 435.06%; the TTM value through Dec 2025 reached 92.97%, down 3016.0%, while the annual FY2025 figure was 92.96%, 3015.0% down from the prior year.
  • EBIT Margin reached 435.06% in Q4 2025 per ARCT's latest filing, down from 96.27% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 75.77% in Q4 2022 to a low of 2711.14% in Q1 2021.
  • Average EBIT Margin over 5 years is 551.52%, with a median of 88.9% recorded in 2022.
  • Peak YoY movement for EBIT Margin: crashed -235355bps in 2021, then soared 260313bps in 2022.
  • A 5-year view of EBIT Margin shows it stood at 649.72% in 2021, then soared by 112bps to 75.77% in 2022, then tumbled by -178bps to 59.22% in 2023, then tumbled by -148bps to 146.68% in 2024, then crashed by -197bps to 435.06% in 2025.
  • Per Business Quant, the three most recent readings for ARCT's EBIT Margin are 435.06% (Q4 2025), 96.27% (Q3 2025), and 41.04% (Q2 2025).